Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy

The introduction of immune checkpoint inhibitors (ICIs) for the treatment of solid cancers dramatically turned the tables in clinical routine. However, therapy success is still limited with up to 70% of non-responders in patients with ICI treatment. Traditionally, most immunotherapy approaches aim a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fendl, B., Berghoff, A.S., Preusser, M., Maier, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024158/
https://www.ncbi.nlm.nih.gov/pubmed/36731326
http://dx.doi.org/10.1016/j.esmoop.2022.100776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024158/
https://www.ncbi.nlm.nih.gov/pubmed/36731326
http://dx.doi.org/10.1016/j.esmoop.2022.100776

Ejemplares similares